Literature DB >> 26550539

Application of (18)F-FDG PET and diffusion weighted imaging (DWI) in multiple myeloma: comparison of functional imaging modalities.

Christos Sachpekidis1, Jennifer Mosebach2, Martin T Freitag2, Thomas Wilhelm2, Elias K Mai3, Hartmut Goldschmidt3, Uwe Haberkorn4, Heinz-Peter Schlemmer2, Stefan Delorme2, Antonia Dimitrakopoulou-Strauss1.   

Abstract

Aim of this prospective study was to assess the sensitivity of positron emission tomography (PET) and diffusion-weighted imaging (DWI) in detecting multiple myeloma (MM) lesions, using the well-established morphologic modalities magnetic resonance imaging (MRI) and computed tomography (CT) as the standard of reference (RS). The study included 24 MM patients (15 newly diagnosed, 9 pre-treated). All underwent (18)F-FDG PET/CT and wholebody DWI. The findings in PET and DWI were compared to matching imaging findings in combined non-enhanced T1w, fat-saturated T2w (TIRM)- MRI, and low-dose CT. Patient-based analysis revealed that 15/24 patients (10 primary MM, 5 pre-treated) had myeloma lesions according to our RS. PET was positive in 13/24 patients (11 primary MM, 2 pre-treated) and DWI in 18/24 patients (12 primary MM, 6 pre-treated). Lesion-based analysis demonstrated 128 MM lesions, of which PET depicted 60/128 lesions (sensitivity 47%), while DWI depicted 99/128 lesions (sensitivity 77%). Further analysis including only the 15 untreated MM patients revealed a sensitivity of 90% for both PET and DWI and an overall concordance of PET and DWI of 72%. In conclusion, DWI was more sensitive than (18)F-FDG PET in detecting myeloma lesions in a mixed population of primary and pre-treated MM patients. However, (18)F-FDG PET and DWI demonstrated equivalent sensitivities in the sub-population of primary, untreated MM patients. This higher sensitivity of DWI in pre-treated patients may be due to the fact that (18)F-FDG PET becomes negative earlier in the course of treatment in contrary to MRI, in which already treated lesions can remain visible.

Entities:  

Keywords:  18F-FDG PET; DWI; Multiple myeloma

Year:  2015        PMID: 26550539      PMCID: PMC4620175     

Source DB:  PubMed          Journal:  Am J Nucl Med Mol Imaging


  42 in total

Review 1.  The role of imaging techniques in the management of multiple myeloma.

Authors:  Elena Zamagni; Michele Cavo
Journal:  Br J Haematol       Date:  2012-08-11       Impact factor: 6.998

Review 2.  Diffusion-weighted magnetic resonance imaging and its application to cancer.

Authors:  Elizabeth M Charles-Edwards; Nandita M deSouza
Journal:  Cancer Imaging       Date:  2006-09-13       Impact factor: 3.909

3.  Separation of diffusion and perfusion in intravoxel incoherent motion MR imaging.

Authors:  D Le Bihan; E Breton; D Lallemand; M L Aubin; J Vignaud; M Laval-Jeantet
Journal:  Radiology       Date:  1988-08       Impact factor: 11.105

4.  Changes in magnetic resonance imaging before and after autologous stem cell transplantation correlate with response and survival in multiple myeloma.

Authors:  Jens Hillengass; Sofia Ayyaz; Kerstin Kilk; Marc-André Weber; Thomas Hielscher; Rajiv Shah; Dirk Hose; Stefan Delorme; Hartmut Goldschmidt; Kai Neben
Journal:  Haematologica       Date:  2012-06-11       Impact factor: 9.941

5.  Performance measurements of the Siemens mMR integrated whole-body PET/MR scanner.

Authors:  Gaspar Delso; Sebastian Fürst; Björn Jakoby; Ralf Ladebeck; Carl Ganter; Stephan G Nekolla; Markus Schwaiger; Sibylle I Ziegler
Journal:  J Nucl Med       Date:  2011-11-11       Impact factor: 10.057

6.  Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3.

Authors:  Meletios Dimopoulos; Robert Kyle; Jean-Paul Fermand; S Vincent Rajkumar; Jesus San Miguel; Asher Chanan-Khan; Heinz Ludwig; Douglas Joshua; Jayesh Mehta; Morie Gertz; Hervé Avet-Loiseau; Meral Beksaç; Kenneth C Anderson; Philippe Moreau; Seema Singhal; Hartmut Goldschmidt; Mario Boccadoro; Shaji Kumar; Sergio Giralt; Nikhil C Munshi; Sundar Jagannath
Journal:  Blood       Date:  2011-02-03       Impact factor: 22.113

Review 7.  PET-based molecular imaging in personalized oncology: potential of the assessment of therapeutic outcome.

Authors:  Antonia Dimitrakopoulou-Strauss
Journal:  Future Oncol       Date:  2015       Impact factor: 3.404

8.  F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma.

Authors:  Twyla B Bartel; Jeff Haessler; Tracy L Y Brown; John D Shaughnessy; Frits van Rhee; Elias Anaissie; Terri Alpe; Edgardo Angtuaco; Ronald Walker; Joshua Epstein; John Crowley; Bart Barlogie
Journal:  Blood       Date:  2009-05-14       Impact factor: 22.113

9.  Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group.

Authors: 
Journal:  Br J Haematol       Date:  2003-06       Impact factor: 6.998

10.  2-[Fluorine-18]-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography versus whole-body diffusion-weighted MRI for detection of malignant lesions: initial experience.

Authors:  Tsuyoshi Komori; Isamu Narabayashi; Kaname Matsumura; Mitsuru Matsuki; Hiroyuki Akagi; Yasuharu Ogura; Fumitoshi Aga; Itaru Adachi
Journal:  Ann Nucl Med       Date:  2007-06-25       Impact factor: 2.668

View more
  22 in total

1.  [(68)Ga]DOTATATE PET/MRI and [(18)F]FDG PET/CT are complementary and superior to diffusion-weighted MR imaging for radioactive-iodine-refractory differentiated thyroid cancer.

Authors:  Alexis Vrachimis; Lars Stegger; Christian Wenning; Benjamin Noto; Matthias Christian Burg; Julia Renate Konnert; Thomas Allkemper; Walter Heindel; Burkhard Riemann; Michael Schäfers; Matthias Weckesser
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-04-08       Impact factor: 9.236

Review 2.  Determination of Minimal Residual Disease in Multiple Myeloma: Does It Matter?

Authors:  Shalin Kothari; Jens Hillengass; Philip L McCarthy; Sarah A Holstein
Journal:  Curr Hematol Malig Rep       Date:  2019-02       Impact factor: 3.952

3.  MRI versus 18F-FDG-PET/CT for detecting bone marrow involvement in multiple myeloma: diagnostic performance and clinical relevance.

Authors:  Frédéric E Lecouvet; Dimitar Boyadzhiev; Laurence Collette; Maude Berckmans; Nicolas Michoux; Perrine Triqueneaux; Vassiliki Pasoglou; François Jamar; Marie-Christiane Vekemans
Journal:  Eur Radiol       Date:  2019-12-16       Impact factor: 5.315

Review 4.  Myeloma Response Assessment and Diagnosis System (MY-RADS): strategies for practice implementation.

Authors:  Michael E Mulligan
Journal:  Skeletal Radiol       Date:  2021-03-06       Impact factor: 2.199

5.  Comparison of qualitative and quantitative CT and MRI parameters for monitoring of longitudinal spine involvement in patients with multiple myeloma.

Authors:  M Horger; J Fritz; W M Thaiss; H Ditt; K Weisel; M Haap; Christopher Kloth
Journal:  Skeletal Radiol       Date:  2017-12-08       Impact factor: 2.199

6.  Optimization of whole-body 2-[18F]FDG-PET/MRI imaging protocol for the initial staging of patients with myeloma.

Authors:  Robert Burns; Sébastien Mulé; Paul Blanc-Durand; Mojdeh Tofighi; Karim Belhadj; Pierre Zerbib; Fabien Le Bras; Laurence Baranes; Corinne Haioun; Emmanuel Itti; Alain Luciani
Journal:  Eur Radiol       Date:  2021-11-29       Impact factor: 5.315

7.  Diffusion-weighted imaging (DWI) in diagnosis, staging, and treatment response assessment of multiple myeloma: a systematic review and meta-analysis.

Authors:  Pooya Torkian; Bahar Mansoori; Jens Hillengass; Javid Azadbakht; Sina Rashedi; Sarah S Lee; Behrang Amini; Pietro Andrea Bonaffini; Majid Chalian
Journal:  Skeletal Radiol       Date:  2022-07-26       Impact factor: 2.128

Review 8.  Imaging in myeloma with focus on advanced imaging techniques.

Authors:  Tara Barwick; Laure Bretsztajn; Kathryn Wallitt; Dimitri Amiras; Andrea Rockall; Christina Messiou
Journal:  Br J Radiol       Date:  2019-01-03       Impact factor: 3.039

9.  Evaluation of bone marrow infiltration in multiple myeloma using whole-body diffusion-weighted imaging and T1-weighted water-fat separation Dixon.

Authors:  Xiaodong Ji; Wenyang Huang; Huazheng Dong; Zhiwei Shen; Meizhu Zheng; Dehui Zou; Wen Shen; Shuang Xia
Journal:  Quant Imaging Med Surg       Date:  2021-02

10.  Comparison of the diagnostic performance and impact on management of 18F-FDG PET/CT and whole-body MRI in multiple myeloma.

Authors:  Olwen Westerland; Ashik Amlani; Christian Kelly-Morland; Michal Fraczek; Katherine Bailey; Mary Gleeson; Inas El-Najjar; Matthew Streetly; Paul Bassett; Gary J R Cook; Vicky Goh
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-01-19       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.